186 related articles for article (PubMed ID: 4070300)
1. Orphan Drug Act.
Van Woert MH
Prog Clin Biol Res; 1985; 197():7-9. PubMed ID: 4070300
[No Abstract] [Full Text] [Related]
2. Orphan Drug Act on congressional agenda.
von Oehsen WH
Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123
[TBL] [Abstract][Full Text] [Related]
3. Generic Pharmaceutical Industry Association Orphan Drug Institute.
Haddad W
Prog Clin Biol Res; 1985; 197():41-5. PubMed ID: 4070298
[No Abstract] [Full Text] [Related]
4. The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development.
Engstrom LO
Prog Clin Biol Res; 1985; 197():25-30. PubMed ID: 4070295
[No Abstract] [Full Text] [Related]
5. Orphan products development and some methods for maximizing the usefulness of research on rare diseases.
Finkel MJ
Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285
[No Abstract] [Full Text] [Related]
6. Should the patent system for new medicines be abolished?
DiMasi JA; Grabowski HG
Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
[No Abstract] [Full Text] [Related]
7. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
Koivuniemi PJ
Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
[No Abstract] [Full Text] [Related]
8. Perspectives. Orphan Drug Act stumps lawmakers.
Firshein J
Faulkner Grays Med Health; 1990 Jun; 44(25):suppl 4 p.. PubMed ID: 10105023
[No Abstract] [Full Text] [Related]
9. Incentives for drug development--the curious case of colchicine.
Kesselheim AS; Solomon DH
N Engl J Med; 2010 Jun; 362(22):2045-7. PubMed ID: 20393164
[No Abstract] [Full Text] [Related]
10. Bush veto fuels orphan drug act uncertainties.
Gershon D
Nature; 1990 Nov; 348(6298):185. PubMed ID: 2234086
[No Abstract] [Full Text] [Related]
11. Academic center approaches to orphan drug research and development.
Hauck FP; Chung EY; Van Woert MH
Prog Clin Biol Res; 1985; 197():115-22. PubMed ID: 4070286
[No Abstract] [Full Text] [Related]
12. The Orphan Drug Act and the Federal Government's Orphan Products Development Program.
Finkel MJ
Public Health Rep; 1984; 99(3):313-6. PubMed ID: 6429731
[TBL] [Abstract][Full Text] [Related]
13. The fuel to run the orphan drug engine: a medical school-based Orphan Disease Center Program.
Brewer GJ
Prog Clin Biol Res; 1985; 197():123-38. PubMed ID: 4070287
[No Abstract] [Full Text] [Related]
14. Improving antibiotic markets for long-term sustainability.
Kesselheim AS; Outterson K
Yale J Health Policy Law Ethics; 2011; 11(1):101-67. PubMed ID: 21381513
[No Abstract] [Full Text] [Related]
15. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1983 Feb; 3(1):47-8. PubMed ID: 6680403
[No Abstract] [Full Text] [Related]
16. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.
Arno PS; Bonuck K; Davis M
Milbank Q; 1995; 73(2):231-52. PubMed ID: 7776947
[TBL] [Abstract][Full Text] [Related]
17. View from the Nation's Capital: the Orphan Drug Act--prospects and problems.
Romansky MA
J Clin Psychopharmacol; 1984 Aug; 4(4):230-2. PubMed ID: 6470200
[No Abstract] [Full Text] [Related]
18. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform.
Clissold DB
Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989
[No Abstract] [Full Text] [Related]
19. Orphan drug development in the United States.
Groft SC
CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306
[TBL] [Abstract][Full Text] [Related]
20. Orphan drug development for the treatment of rare chronic diseases.
Moore ES
Tex Hosp; 1988 Jul; 44(2):20-1. PubMed ID: 10288218
[No Abstract] [Full Text] [Related]
[Next] [New Search]
